Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Breast Cancer Research : BCR|April 8, 2020
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implicationsClaudio Vernieri, Francesca Corti, Federico Nichetti, et al.
Frontiers in Oncology|January 12, 2019
CDK 4/6 Inhibitors as Single Agent in Advanced Solid TumorsFrancesco Schettini, Irene De Santo, Carmen G Rea, et al.
Molecular and Clinical Oncology|April 8, 2020
Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report seriesFrancesco Schettini, Irene De Santo, Carmen G Rea, et al.
Therapeutic Advances in Medical Oncology|December 18, 2020
Antitumor activity and efficacy of shorter <i>versus</i> longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysisRiccardo Lobefaro, Emma Zattarin, Federico Nichetti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2021
Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET)Claudio Vernieri, Federico Nichetti, Luca Lalli, et al.
Pageof 1